Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib

<b>Background:</b> Although nilotinib hepatotoxicity can cause severe clinical conditions and may alter treatment plans, risk factors affecting nilotinib-induced hepatotoxicity have not been investigated. This study aimed to elucidate the factors affecting nilotinib-induced hepatotoxicit...

Full description

Bibliographic Details
Main Authors: Jung-Sun Kim, Ji-Min Han, Yoon-Sook Cho, Kyung-Hee Choi, Hye-Sun Gwak
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Molecules
Subjects:
Online Access:https://www.mdpi.com/1420-3049/26/11/3300
id doaj-14cbd0cfe5bf494dbf21a6a7f9807b0d
record_format Article
spelling doaj-14cbd0cfe5bf494dbf21a6a7f9807b0d2021-06-01T01:42:22ZengMDPI AGMolecules1420-30492021-05-01263300330010.3390/molecules26113300Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving NilotinibJung-Sun Kim0Ji-Min Han1Yoon-Sook Cho2Kyung-Hee Choi3Hye-Sun Gwak4College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, KoreaCollege of Pharmacy, Chungbuk National University, Cheongju-si 28160, KoreaDepartment of Pharmacy, Seoul National University Hospital, Seoul 03080, KoreaCollege of Pharmacy, Sunchon National University, Suncheon 57922, KoreaCollege of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul 03760, Korea<b>Background:</b> Although nilotinib hepatotoxicity can cause severe clinical conditions and may alter treatment plans, risk factors affecting nilotinib-induced hepatotoxicity have not been investigated. This study aimed to elucidate the factors affecting nilotinib-induced hepatotoxicity. <b>Methods:</b> This retrospective cohort study was performed on patients using nilotinib from July of 2015 to June of 2020. We estimated the odds ratio and adjusted odds ratio from univariate and multivariate analyses, respectively. Several machine learning models were developed to predict risk factors of hepatotoxicity occurrence. The area under the curve (AUC) was analyzed to assess clinical performance. <b>Results:</b> Among 353 patients, the rate of patients with grade I or higher hepatotoxicity after nilotinib administration was 40.8%. Male patients and patients who received nilotinib at a dose of ≥300 mg had a 2.3-fold and a 3.5-fold increased risk for hepatotoxicity compared to female patients and compared with those who received <300 mg, respectively. H2 blocker use decreased hepatotoxicity by 11.6-fold. The area under the curve (AUC) values of machine learning methods ranged between 0.61–0.65 in this study. <b>Conclusion:</b> This study suggests that the use of H2 blockers was a reduced risk of nilotinib-induced hepatotoxicity, whereas male gender and a high dose were associated with increased hepatotoxicity.https://www.mdpi.com/1420-3049/26/11/3300nilotinibhepatotoxicitymaleH2 blockerdosemachine learning
collection DOAJ
language English
format Article
sources DOAJ
author Jung-Sun Kim
Ji-Min Han
Yoon-Sook Cho
Kyung-Hee Choi
Hye-Sun Gwak
spellingShingle Jung-Sun Kim
Ji-Min Han
Yoon-Sook Cho
Kyung-Hee Choi
Hye-Sun Gwak
Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib
Molecules
nilotinib
hepatotoxicity
male
H2 blocker
dose
machine learning
author_facet Jung-Sun Kim
Ji-Min Han
Yoon-Sook Cho
Kyung-Hee Choi
Hye-Sun Gwak
author_sort Jung-Sun Kim
title Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib
title_short Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib
title_full Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib
title_fullStr Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib
title_full_unstemmed Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib
title_sort machine learning approaches to predict hepatotoxicity risk in patients receiving nilotinib
publisher MDPI AG
series Molecules
issn 1420-3049
publishDate 2021-05-01
description <b>Background:</b> Although nilotinib hepatotoxicity can cause severe clinical conditions and may alter treatment plans, risk factors affecting nilotinib-induced hepatotoxicity have not been investigated. This study aimed to elucidate the factors affecting nilotinib-induced hepatotoxicity. <b>Methods:</b> This retrospective cohort study was performed on patients using nilotinib from July of 2015 to June of 2020. We estimated the odds ratio and adjusted odds ratio from univariate and multivariate analyses, respectively. Several machine learning models were developed to predict risk factors of hepatotoxicity occurrence. The area under the curve (AUC) was analyzed to assess clinical performance. <b>Results:</b> Among 353 patients, the rate of patients with grade I or higher hepatotoxicity after nilotinib administration was 40.8%. Male patients and patients who received nilotinib at a dose of ≥300 mg had a 2.3-fold and a 3.5-fold increased risk for hepatotoxicity compared to female patients and compared with those who received <300 mg, respectively. H2 blocker use decreased hepatotoxicity by 11.6-fold. The area under the curve (AUC) values of machine learning methods ranged between 0.61–0.65 in this study. <b>Conclusion:</b> This study suggests that the use of H2 blockers was a reduced risk of nilotinib-induced hepatotoxicity, whereas male gender and a high dose were associated with increased hepatotoxicity.
topic nilotinib
hepatotoxicity
male
H2 blocker
dose
machine learning
url https://www.mdpi.com/1420-3049/26/11/3300
work_keys_str_mv AT jungsunkim machinelearningapproachestopredicthepatotoxicityriskinpatientsreceivingnilotinib
AT jiminhan machinelearningapproachestopredicthepatotoxicityriskinpatientsreceivingnilotinib
AT yoonsookcho machinelearningapproachestopredicthepatotoxicityriskinpatientsreceivingnilotinib
AT kyungheechoi machinelearningapproachestopredicthepatotoxicityriskinpatientsreceivingnilotinib
AT hyesungwak machinelearningapproachestopredicthepatotoxicityriskinpatientsreceivingnilotinib
_version_ 1721411759468707840